A new trading day began on Monday, with Akebia Therapeutics Inc (NASDAQ: AKBA) stock price up 5.19% from the previous day of trading, before settling in for the closing price of $1.54. AKBA’s price has ranged from $1.45 to $4.08 over the past 52 weeks.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 32.58%. Meanwhile, its annual earnings per share averaged 112.73%. With a float of $256.75 million, this company’s outstanding shares have now reached $265.23 million.
Akebia Therapeutics Inc (AKBA) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Akebia Therapeutics Inc is 3.25%, while institutional ownership is 47.42%. The most recent insider transaction that took place on Jun 30 ’25, was worth 151,622. In this transaction SVP, CFO, CBO & Treasurer of this company sold 41,314 shares at a rate of $3.67, taking the stock ownership to the 503,586 shares. Before that another transaction happened on Jun 30 ’25, when Company’s Officer proposed sale 41,314 for $3.67, making the entire transaction worth $151,622.
Akebia Therapeutics Inc (AKBA) Recent Fiscal highlights
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.1 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 112.73% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Here are Akebia Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.91. Likewise, its price to free cash flow for the trailing twelve months is 13.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.08, a number that is poised to hit 0.00 in the next quarter and is forecasted to reach 0.12 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Compared to the last year’s volume of 4.17 million, its volume of 3.6 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 69.17%.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 6.74%, which indicates a significant decrease from 57.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0932 in the past 14 days, which was lower than the 0.1411 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.2650, while its 200-day Moving Average is $2.7135. Nevertheless, the first resistance level for the watch stands at $1.6500 in the near term. At $1.6800, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.7400. If the price goes on to break the first support level at $1.5600, it is likely to go to the next support level at $1.5000. Now, if the price goes above the second support level, the third support stands at $1.4700.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
With a market capitalization of 429.89 million, the company has a total of 265,366K Shares Outstanding. Currently, annual sales are 160,180 K while annual income is -69,410 K. The company’s previous quarter sales were 58,770 K while its latest quarter income was 540 K.
